ALLO News and Press, Allogene Therapeutics Inc. From 12/11/20

The following slide deck was published by Allogene Therapeutics, Inc. in conjunction with this event. For further details see: Allogene Therapeutics (ALLO) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow

Two pre-clinical successes by Allogene Therapeutics (NASDAQ:ALLO) as announced at the ongoing Annual Meeting of the American Society of Hematology has failed to pique investor interest with share down ~11% on above average volume.The company headquartered in South San Francisco pioneers the d...

Allogene Therapeutics ([[ALLO]] -13.3%) slumps as investors appear disappointed to interim results from Phase 1 trial, UNIVERSAL, evaluating ALLO-715, anti-CD52 monoclonal antibody with ALLO-647 lymphodepletion, for relapsed/refractory multiple myeloma. Data were presented...

ALLO-605 Demonstrated Enhanced Killing of Multiple Myeloma Cells and Persistence Relative to BCMA CAR T TurboCAR Technology Represents a Key Component to the Company’s Three-Pronged Clinical Strategy Targeting BCMA for Multiple Myeloma Investigational New Drug (IND) Appli...

Results Demonstrate Ability of AlloCAR T™ Therapy to Selectively Kill CD70 Expressing Leukemic Cells Coupled with Previous Findings in Renal Cell Carcinoma (RCC), Results Highlight the Potential of ALLO-316 to Treat Both Hematologic Malignancies and Solid Tumors Investiga...

First Reported Allogeneic CAR T Data in Multiple Myeloma Highlights Initial Safety and Efficacy in Heavily Pretreated, Refractory Patients In the Ongoing Study, 31 Patients Were Evaluable for Safety and 26 Patients Were Evaluable for Efficacy as of Data Cutoff Approximately 90% of...

Webinar Scheduled for 11:00 AM PT/2:00 PM ET SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, tod...

Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 months to further elucidate safety and efficacy. The combination of high clinical f...

Pfizer has been working on New Pfizer for almost a decade. The spin offs of Consumer Health and Upjohn appear to be the last steps. Continuation of the policy of dividend growth is a stated priority. Biopharma led by scientific pipeline innovation is expected to generate $15 ...

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in ...